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Mutations causing X-linked severe combined immunodeficiency (SCID-X1) reduce immune cell populations
and function andmay be amenable to targeted gene correction strategies. Now inCell StemCell, Menon et al.
(2015) correct SCID-X1-related blood differentiation defects by TALEN-mediated genome editing in patient-
derived iPSCs, suggesting a possible strategy for autologous cell therapy of SCID-X1.X-linked severe combined immunodefi-
ciency (SCID-X1) is a primary immunode-
ficiency with severe prognosis of death
occurring within a few years after birth.
Affected patients carry inactivating muta-
tions in the interleukin-2 receptor gamma
chain (IL2RG) gene, resulting in immune
defects including lack of T cells, functional
B cells, and NK cells. Transplantation of
HLA-matched hematopoietic stem cells
(HSCs) from healthy donors provides
substantial clinical benefit, with an overall
survival of 85%–90% in subjects re-
ceiving transplants from matched-sibling
donors (Antoine et al., 2003; Gennery
et al., 2010; Brown et al., 2011). Survival
rates are significantly lower, and trans-
plant-related morbidity is increased,
when cells from mismatched related do-
nors, matched unrelated donors, or um-
bilical-cord-blood donors are employed
or patients experience severe infections
at time of transplantation (Brown et al.,
2011). Now in Cell Stem Cell, Menon
et al. (2015) suggest an innovative strat-
egy for the development of an autologous
cell therapy for SCID-X1.
SCID-X1 represents a suitable and
attractive setting for the clinical transla-
tion of targeted gene correction strate-
gies and adoptive transfer of gene-
corrected cells, as cells bearing a
functional gamma chain show a positive
selective advantage in vivo in the affected
patients (Hacein-Bey-Abina et al., 2002).
Previously, gene therapy based on the
transplantation of autologous gene-cor-
rected HSCs has been attempted in
SCID-X1 patients who did not have
matched family donors. These patients
received autologous HSCs transduced
with a first-generation Moloney murine
leukemia virus vector (Hacein-Bey-Abina348 Cell Stem Cell 16, April 2, 2015 ª2015 Elet al., 2002, 2003) and, more recently,
with a self-inactivating (SIN) retroviral
vector (Hacein-Bey-Abina et al., 2014)
expressing IL2RG cDNA. In both cases,
gene therapy resulted in a favorable
clinical outcome, although patients re-
ceiving the first-generation retroviral
vector developed acute lymphoblastic
leukemia with an incidence rate of 25%,
arising from insertional mutagenesis of
the vector (Hacein-Bey-Abina et al.,
2003). The limited follow-up of the pa-
tients treated with the SIN vector does
not yet allow definitive conclusions on
the long-term risk of vector-related leuke-
mogenesis in this latter case.
One goal of gene therapy is to restore
not only the function but also the physio-
logical levels of expression of the target
gene. In situ replacement of disease-
causing gene mutations by homologous
recombination is expected to achieve
this goal and provide therapeutic benefit
without potential accompanying com-
plications such as insertional oncogen-
esis, transgene silencing, or inappropriate
gene expression. In a recent proof of
concept study, exon 5 of the IL2RG
gene, a hotspot for SCID-X1 mutations,
was targeted in HSCs and progenitor
cells from healthy donors and an SCID-
X1 patient using zinc finger nucleases
(ZFNs) (Genovese et al., 2014). This re-
sulted in successful reconstitution of a
functional IL2RG gene with remarkably
high efficiency (Genovese et al., 2014)
and encouraged potentially moving this
approach toward the clinic. However, is-
sues such as the availability of a poten-
tially limiting number of gene-corrected
stem cells may constitute a challenge
for the clinical translation of this strategy
for SCID-X1 correction. Moreover, ZFNssevier Inc.may have potential off-target activity that
could be of clinical relevance.
Now in Cell Stem Cell, Menon, Firth,
and colleagues (Menon et al., 2015)
demonstrate that genetically corrected
mature lymphoid cells can be generated
in vitro with transcription activator-
like effector nuclease (TALEN)-mediated
genome editing in induced pluripotent
stem cells (iPSCs) derived from a SCID-
X1 subject. iPSC lines were generated
from mesenchymal bone marrow cells
of the subject using Cre-excisable lentivi-
ral vectors encoding six reprogramming
factors, and then the subject’s specific
mutation was corrected using TALEN
pairs targeting genomic sequences prox-
imal to the mutation. Of note, such an
approach allows the reprogramming fac-
tors to be eventually excised before
gene correction, strengthening its clin-
ical transferability. The use of TALENs
for gene correction may further improve
the path to clinical translation of this
approach, as the ease and speed of
genome editing achieved with this tech-
nology may alleviate concerns such as
off-target effects. Importantly, correction
of IL2RG mutations in subject iPSCs
allowed generation of T cell precursors
andmature NK cells after long-term differ-
entiation in vitro. Significantly, these cell
populations were abnormal or absent in
the subject and could not be obtained
by differentiating non-corrected control
iPSCs from the same individual.
In addition to the technical improve-
ments resulting from optimized in vitro
differentiation protocols, these results
are of great clinical relevance. The data
from Menon, Firth, and colleagues
demonstrate that engineered iPSCs
could be a valuable source of autologous,
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cells for adoptive transfer, as a support-
ive and/or possibly curative treatment
for SCID-X1. The T and NK populations
in SCID-X1 subjects are numerically
and functionally reduced, and supple-
mentation of these populations with their
gene-corrected, iPSC-derived counter-
parts could provide substantial clinical
benefit to subjects, including prevention
and treatment of infections. Importantly,
the survival advantage conferred onto
the adoptively transferred in vitro prog-
eny of the iPSCs by gene correction
would constitute a critical advantage of
this approach when tested in subjects.
Beyond SCID-X1, adoptive transfer of
NK and T-precursor cells is being evalu-
ated in individuals with cancer and could
potentially provide great benefit to immu-
nodeficient patients, as shown for adeno-
sine deaminase deficiency (Aiuti et al.,
2002).
Derivation of mature immune cells from
stable, gene corrected, autologous iPSCs
could successfully address many of the
issues raised by clinical experience of
adoptive cell transfer. Such an approach
could resolve issues related to the avail-
ability of allogeneic cells, the lack of
adequate cell numbers, and the need for
efficient gene correction into mature cellswhile removing the risks related to the use
of integrating vectors in traditional gene
therapy approaches. However, several
challenges must be addressed to trans-
late these findings to the clinic. Critical is-
sues in iPSC generation and differentia-
tion (i.e., reproducibility and consistency
across subjects and the need for func-
tional characterization of the mature
gene-corrected cells to be employed for
adoptive transfer) and in gene correction
(i.e., the efficiency by which the desired
genetic modification can be achieved in
the target cell population and the limited
tolerance of the cells to DNA double-
strand breaks) must be resolved, and
optimizing protocols to scale up pro-
cesses to obtain the amounts of cells
required to treat patients is of the utmost
importance. With these challenges in
mind, the findings of Menon et al. provide
exciting perspectives for the development
of new therapies based on adoptive
transfer of autologous cells fixed in their
mutations for people affected by genetic
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